Core Insights - Arcutis Biotherapeutics' product ZORYVE has received the 2025 Best of Beauty Breakthrough Award from Allure magazine, marking it as the first prescription topical medication for eczema, plaque psoriasis, and seborrheic dermatitis to achieve this recognition [1][6][9] Company Overview - Arcutis Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on innovations in immuno-dermatology, with a commitment to addressing urgent patient needs in dermatological conditions [17] Product Highlights - ZORYVE is recognized for its unique profile in dermatology, being the number one prescribed branded topical therapy for eczema, plaque psoriasis, and seborrheic dermatitis [3][7][9] - The product is a highly selective and potent phosphodiesterase-4 (PDE4) inhibitor, designed to be safe and effective for various inflammatory skin diseases [4][10] - ZORYVE is available in a once-daily, steroid-free topical foam or cream formulation that can be applied anywhere on the body, suitable for all skin and hair types [4][11] Award Significance - The Allure Best of Beauty Breakthrough Award is a prestigious honor, with fewer than 10 products typically winning in this category, highlighting ZORYVE's revolutionary impact on skincare [6][9] Clinical and Safety Information - ZORYVE has been shown to be safe and well-tolerated, providing rapid symptom relief and has been prescribed over 1 million times by healthcare providers [9][11] - The product is indicated for use in patients aged 6 years and older for various conditions, including mild to moderate atopic dermatitis and plaque psoriasis [12][13]